Financials data is unavailable for this security.
View more
Year on year Panion & BF Biotech Inc 's revenues fell -21.54% from 2.40bn to 1.88bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 182.35m to 77.22m, a -57.65% decrease.
Gross margin | 52.66% |
---|---|
Net profit margin | 5.04% |
Operating margin | 9.62% |
Return on assets | 3.12% |
---|---|
Return on equity | 5.43% |
Return on investment | 4.82% |
More ▼
Cash flow in TWDView more
In 2023, Panion & BF Biotech Inc increased its cash reserves by 15.16%, or 70.37m. The company earned 177.42m from its operations for a Cash Flow Margin of 9.43%. In addition the company generated 48.67m cash from financing while 155.27m was spent on investing.
Cash flow per share | 3.18 |
---|---|
Price/Cash flow per share | 27.95 |
Book value per share | 21.62 |
---|---|
Tangible book value per share | 21.50 |
More ▼
Balance sheet in TWDView more
Current ratio | 1.34 |
---|---|
Quick ratio | 0.8699 |
Total debt/total equity | 0.4024 |
---|---|
Total debt/total capital | 0.287 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -25.00% and -57.63%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
Div yield(5 year avg) | 1.47% |
---|---|
Div growth rate (5 year) | -3.23% |
Payout ratio (TTM) | 127.00% |
EPS growth(5 years) | -15.14 |
---|---|
EPS (TTM) vs TTM 1 year ago | 372.83 |
More ▼